RCKT
Rocket Pharmaceuticals, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Rocket Pharmaceuticals has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIn March 2016, we entered into a license agreement with CIEMAT Group, granting us worldwide, exclusive rights to certain patents, know-how and other intellectual property relating to LVs containing the human PKLR gene solely within the field of treating PKD.
RCKT 10-Kaccession 0001193125-26-076551
SentenceAs of December 31, 2025, the Company has received RP-A501 grants of $5.0 million from CIRM.
RCKT 10-Kaccession 0001193125-26-076551
SentenceOn November 19, 2018, we entered into a license agreement with RGNX, pursuant to which we obtained an exclusive license for all U.S. patents and patent applications related to RGNX's NAV AAV-9 vector for the treatment of DD in humans by in vivo gene therapy using AAV-9 to deliver any known LAMP2 transgene isoforms and all possible combinations of LAMP2 transgene isoforms, as well as an exclusive option to license all U.S. patents and patent applications for two additional NAV AAV vectors.
RCKT 10-Kaccession 0001193125-26-076551
SentenceOn December 1, 2022, we acquired Renovacor, including a license agreement for BAG3 with Temple University.
RCKT 10-Kaccession 0001193125-26-076551
SentenceIn February 2017, we entered into a license agreement with The Regents of the University of California, represented by its San Diego campus, under which UCSD granted us an exclusive, sublicensable, worldwide license to certain intellectual property rights for the treatment of lysosomal storage diseases, including DD.
RCKT 10-Kaccession 0001193125-26-076551
−3.85%
vs ±29.1% implied · ×0.13
shaded = implied · ▲▼ = realized
Rocket Pharmaceuticals, Inc.
2.44
Largest filed tie
—
—
—
Expected move
Inputs8Q avg ±3.4%·×10.35·rich
straddle ±37.4%
spot 2.44exp Nov 20ATM strike 2.5ATM straddle 1.07IV 230%